Skip to main content
ALXO
NASDAQ Life Sciences

Nature Medicine Publishes ASPEN-06 Data: Evorpacept Shows 40.3% ORR in HER2+ Gastric Cancer

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$1.3
Mkt Cap
$181.143M
52W Low
$1.05
52W High
$2.66
52W Position info
24% above low
Off High info
51% below high
Rel. Volume info
1.2× avg
Market data snapshot near publication time

ALXO sits 24% above its 52-week low of $1.05.

Summary

ALX Oncology announced publication of ASPEN-06 Phase 2 data in Nature Medicine, showing evorpacept plus TRP achieved 40.3% ORR vs 26.6% for control in HER2-positive gastric cancer. In patients with retained HER2 and high CD47 expression, ORR jumped to 63.6% vs 23.1%, with median PFS of 19.5 vs 7.0 months. The company also disclosed it will not pursue a U.S. registrational path in gastric cancer and will seek partnerships, while advancing the ASPEN-09-Breast trial with topline data expected mid-2027. This is the first detailed disclosure of these results and the strategic decision, following a narrower Q2 loss reported in August. The biomarker-driven data strengthens the case for evorpacept in breast cancer, but the lack of a registrational path in gastric cancer tempers the near-term commercial outlook.

At the time of this announcement, ALXO was trading at $1.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $181.1M. The 52-week trading range was $1.05 to $2.66. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

ALXO - Latest Insights

ALXO
Oct 15, 2026, 4:55 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.9709
Real-time Price: $0.994 info
Change: +$0.0231 (+2%) info
Market Cap: $137.031M info
ALXO
Aug 06, 2026, 8:16 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $0.994 info
Change: -$0.926 (-48%) info
Market Cap: $137.031M info
ALXO
Aug 06, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.92
Real-time Price: $0.994 info
Change: -$0.926 (-48%) info
Market Cap: $137.031M info
ALXO
Jun 30, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.07
Real-time Price: $0.994 info
Change: -$1.08 (-52%) info
Market Cap: $137.031M info
ALXO
Jun 30, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.07
Real-time Price: $0.994 info
Change: -$1.08 (-52%) info
Market Cap: $137.031M info